These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 32958250)

  • 41. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
    Fu L; Ye F; Feng Y; Yu F; Wang Q; Wu Y; Zhao C; Sun H; Huang B; Niu P; Song H; Shi Y; Li X; Tan W; Qi J; Gao GF
    Nat Commun; 2020 Sep; 11(1):4417. PubMed ID: 32887884
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Not Available].
    Nau JY
    Rev Med Suisse; 2020 Mar; 16(685):510-511. PubMed ID: 32167254
    [No Abstract]   [Full Text] [Related]  

  • 43. Potential Antiviral Options against SARS-CoV-2 Infection.
    Ianevski A; Yao R; Fenstad MH; Biza S; Zusinaite E; Reisberg T; Lysvand H; Løseth K; Landsem VM; Malmring JF; Oksenych V; Erlandsen SE; Aas PA; Hagen L; Pettersen CH; Tenson T; Afset JE; Nordbø SA; Bjørås M; Kainov DE
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32545799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Gordon DE; Jang GM; Bouhaddou M; Xu J; Obernier K; White KM; O'Meara MJ; Rezelj VV; Guo JZ; Swaney DL; Tummino TA; Hüttenhain R; Kaake RM; Richards AL; Tutuncuoglu B; Foussard H; Batra J; Haas K; Modak M; Kim M; Haas P; Polacco BJ; Braberg H; Fabius JM; Eckhardt M; Soucheray M; Bennett MJ; Cakir M; McGregor MJ; Li Q; Meyer B; Roesch F; Vallet T; Mac Kain A; Miorin L; Moreno E; Naing ZZC; Zhou Y; Peng S; Shi Y; Zhang Z; Shen W; Kirby IT; Melnyk JE; Chorba JS; Lou K; Dai SA; Barrio-Hernandez I; Memon D; Hernandez-Armenta C; Lyu J; Mathy CJP; Perica T; Pilla KB; Ganesan SJ; Saltzberg DJ; Rakesh R; Liu X; Rosenthal SB; Calviello L; Venkataramanan S; Liboy-Lugo J; Lin Y; Huang XP; Liu Y; Wankowicz SA; Bohn M; Safari M; Ugur FS; Koh C; Savar NS; Tran QD; Shengjuler D; Fletcher SJ; O'Neal MC; Cai Y; Chang JCJ; Broadhurst DJ; Klippsten S; Sharp PP; Wenzell NA; Kuzuoglu-Ozturk D; Wang HY; Trenker R; Young JM; Cavero DA; Hiatt J; Roth TL; Rathore U; Subramanian A; Noack J; Hubert M; Stroud RM; Frankel AD; Rosenberg OS; Verba KA; Agard DA; Ott M; Emerman M; Jura N; von Zastrow M; Verdin E; Ashworth A; Schwartz O; d'Enfert C; Mukherjee S; Jacobson M; Malik HS; Fujimori DG; Ideker T; Craik CS; Floor SN; Fraser JS; Gross JD; Sali A; Roth BL; Ruggero D; Taunton J; Kortemme T; Beltrao P; Vignuzzi M; García-Sastre A; Shokat KM; Shoichet BK; Krogan NJ
    Nature; 2020 Jul; 583(7816):459-468. PubMed ID: 32353859
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.
    Huang Y; Yang C; Xu XF; Xu W; Liu SW
    Acta Pharmacol Sin; 2020 Sep; 41(9):1141-1149. PubMed ID: 32747721
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Yao X; Ye F; Zhang M; Cui C; Huang B; Niu P; Liu X; Zhao L; Dong E; Song C; Zhan S; Lu R; Li H; Tan W; Liu D
    Clin Infect Dis; 2020 Jul; 71(15):732-739. PubMed ID: 32150618
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.
    Xie X; Muruato AE; Zhang X; Lokugamage KG; Fontes-Garfias CR; Zou J; Liu J; Ren P; Balakrishnan M; Cihlar T; Tseng CK; Makino S; Menachery VD; Bilello JP; Shi PY
    Nat Commun; 2020 Oct; 11(1):5214. PubMed ID: 33060595
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.
    Rizzo E
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Jul; 393(7):1153-1156. PubMed ID: 32462282
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chloroquine as a prophylactic agent against COVID-19?
    Gendrot M; Javelle E; Clerc A; Savini H; Pradines B
    Int J Antimicrob Agents; 2020 Jun; 55(6):105980. PubMed ID: 32294495
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Roles of flavonoids against coronavirus infection.
    Russo M; Moccia S; Spagnuolo C; Tedesco I; Russo GL
    Chem Biol Interact; 2020 Sep; 328():109211. PubMed ID: 32735799
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway.
    Ma Q; Li R; Pan W; Huang W; Liu B; Xie Y; Wang Z; Li C; Jiang H; Huang J; Shi Y; Dai J; Zheng K; Li X; Hui M; Fu L; Yang Z
    Phytomedicine; 2020 Nov; 78():153296. PubMed ID: 32890913
    [TBL] [Abstract][Full Text] [Related]  

  • 53. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
    Andreou A; Trantza S; Filippou D; Sipsas N; Tsiodras S
    In Vivo; 2020 Jun; 34(3 Suppl):1567-1588. PubMed ID: 32503814
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of SARS-CoV-2 by type I and type III interferons.
    Felgenhauer U; Schoen A; Gad HH; Hartmann R; Schaubmar AR; Failing K; Drosten C; Weber F
    J Biol Chem; 2020 Oct; 295(41):13958-13964. PubMed ID: 32587093
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
    Zhao X; Zheng S; Chen D; Zheng M; Li X; Li G; Lin H; Chang J; Zeng H; Guo JT
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641482
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovering small-molecule therapeutics against SARS-CoV-2.
    Tiwari V; Beer JC; Sankaranarayanan NV; Swanson-Mungerson M; Desai UR
    Drug Discov Today; 2020 Aug; 25(8):1535-1544. PubMed ID: 32574699
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lactoferrin as potential preventative and adjunct treatment for COVID-19.
    Chang R; Ng TB; Sun WZ
    Int J Antimicrob Agents; 2020 Sep; 56(3):106118. PubMed ID: 32738305
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein.
    Yang C; Pan X; Xu X; Cheng C; Huang Y; Li L; Jiang S; Xu W; Xiao G; Liu S
    Signal Transduct Target Ther; 2020 Oct; 5(1):220. PubMed ID: 33024075
    [No Abstract]   [Full Text] [Related]  

  • 59. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.
    Ma Q; Pan W; Li R; Liu B; Li C; Xie Y; Wang Z; Zhao J; Jiang H; Huang J; Shi Y; Dai J; Zheng K; Li X; Yang Z
    Pharmacol Res; 2020 Aug; 158():104850. PubMed ID: 32360580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.